Drug Discovery Today - the magazine for the drug discovery professional: authoritative reviews and expert opinion; industry focused and peer reviewed.

Latest News

ELRIG UK Establishes Engagement Strategy Work Group
Group aims to improve access to scientific programmes and grow ELRIG community
BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides
Taipei, Taiwan, 13th September 2023 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885), a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint diseases, announced today that 22,500 shares have been issued at a premium of NT$65 (~US$2.03), raising a total of NT$1.4625 billion (~US$45.8 million). The rights issue was fully paid on 31st August 2023, four days early compared to the scheduled date of 4th September.
Discovery Park welcomes decision to re-join EU Horizon science programme
Sandwich, UK, 7th September 2023 / Sciad Newswire / Discovery Park, Kent’s thriving life science community, welcomes today’s announcement that the UK will re-join the EU’s Horizon science research programme.
IChemE announces 2023 Global Awards finalists
Professional excellence, positive environmental impact, process safety and societal benefit are among the key qualities being celebrated by the Institution of Chemical Engineers (IChemE) as it announces the finalists for its 2023 Global Awards.
Longevity Biotech Startup Gero Demonstrates the Power of Quantum Computing in Drug Design
Research published in Nature Scientific Reports builds on earlier work and demonstrates that commercially available quantum computing services can dramatically accelerate discovery of a new universe of unique chemical structures that are synthetically feasible and possess drug-like properties for tackling complex diseases and aging

Podcasts

Evotec strengthens and expands its Alliance Business
Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology.
The Ubiquitin Story
In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
Download the Califf, Behrman and Kramer podcast as an mp3 file
Dr Brent Vose outlines AstraZeneca's oncology pipeline.
Download the Dr. Brent Vose podcast as an mp3 file

Webinars

The Promise of Epigenetics in Early Stage Drug Discovery
Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
Drug Delivery: enabling technology for discovery and development
The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.

Features

Peptide therapeutics: current statusand future directions
Here, the authors discuss the current status, strengths, and weaknesses of peptides as medicines and the emerging new opportunities in peptide drug design and development.
Getting the most out of your IP – patent management along its life cycle
We discover that successful patent portfolio management is rooted in managing the patents along their life cycles.
What makes a good drug target? What makes a good drug target?
In this article, Isabella Gashaw , Peter Ellinghaus, Anette Sommer and Khusru Asadullah discuss those factors that differentiate good drug targets from poor or the unusable.
Drug discovery in the next decade:innovation needed ASAP
The pharmaceutical sector, a cornerstone of the healthcare industry, is undergoing dramaticchange, primarily caused by reduced output of new medicines from research and development(R&D) laboratories, drug pricing pressures, stricter regulatory environments and the overallcurrent economic downturn. This makes demands of all pharmaceutical companies to find better ways to increase their output of new drugs, through innovation, to both treat patients and meet their shareholders’ expectations.

Downloads

Brain-derived neurotrophic factor (BDNF) in perinatal depression: side show or pivotal factor?
Perinatal depression is the most common psychiatric complication of pregnancy. This study reviews the role of BDNF in reproductive biology and its pregnancy-related changes as a surrogate endpoint for translational and clinical studies of depression.
Translating Precision Medicine for Autism Spectrum Disorder: A Pressing Need
High genetic and clinical heterogeneity has rendered existing drug discovery efforts inefficient for patients with neurodevelopmental disorders, highlighting the need for omics- and endophenotyping-based approaches in patient diagnosis and treatment.
Inflammation, stress and depression: an exploration of ketamine’s therapeutic profile
This review investigates the role of inflammation in chronic stress and depression, as well as how the rapid-acting antidepressant ketamine can exert some of its therapeutic effects via anti-inflammatory mechanisms.
Emerging trends in pulmonary delivery of biopharmaceuticals
Pulmonary delivery of biopharmaceuticals is a niche area of the current pharmaceutical market holding immense scope for drug discovery and development. To combat the limitation-driven conventional treatments, pulmonary administration of biopharmaceuticals has navigated remarkable change in targeted drug delivery
Engineering nanoparticle therapeutics for impaired wound healing in diabetes
We focus on emerging nanotherapeutics capable of addressing the pathophysiology of chronic wounds in diabetes to better manage the impaired healing that current clinical treatments fail to address.

25 Hottest Articles

Peptide therapeutics: current status and future directions • Review article
Drug Discovery Today, Volume 20, Issue 1, Pages 122-128 | Fosgerau, K.; Hoffmann, T.
Bispecific antibodies • Review article
Drug Discovery Today, Volume 20, Issue 7, Pages 838-847 | Kontermann, R.E.; Brinkmann, U.
Designing novel building blocks is an overlooked strategy to improve compound quality • Review article
Drug Discovery Today, Volume 20, Issue 1, January 2015, Pages 11-17 | Goldberg, F.W.; Kettle, J.G.; Kogej, T.; Perry, M.W.D.; Tomkinson, N.P.
The road ahead for large pharma: long-term science and innovation • Editorial
Drug Discovery Today, Volume 14, Issue 9-10, May 2009, Pages 439-441 | Lundberg, J.M.; Reilly, C.
The impact of aromatic ring count on compound developability - are too many aromatic rings a liability in drug design? • Review article
Drug Discovery Today, Volume 14, Issue 21-22, November 2009, Pages 1011-1020 | Ritchie, T.J.; Macdonald, S.J.F.

Latest News

Podcasts

Webinars

Features

Downloads

25 Hottest Articles

There is a US version of this site available...